With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

By comparison, the FDA-approved drug liraglutide only resulted in just under 6% weight loss after 26 weeks, the researchers ...

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

GLP-1 receptor agonist weight loss drugs can negatively interact with eating disorder psychopathology and treatment in ...

According to the Company, the generic product will launch immediately. The Food and Drug Administration (FDA) has approved Liraglutide Injection, the first generic version of Victoza ®.

Hopefully, the approval will help prevent shortages triggered by demand for injectable weight loss drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) There is still ...